Fall Clinical Dermatology, 2024

Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials

Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II

Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II

Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT

Barriers and Facilitators to Quality HS Biologic Care and Outcomes for the Medicaid Population Across US States

Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT

Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods

Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT

Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial

Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials

Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicenter, randomized, open-label studies